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Cytokine polymorphisms may contribute to the prevalence of respiratory distress syndrome. The present study was done to
investigate the frequency of interleukin- (IL-) 10 and tumor necrosis factor- (TNF-) 𝛼 gene polymorphisms and their association
with the risk of RDS in preterm infants. One-hundred andnineteen patientswithRDS and 119 healthy preterm infantswere enrolled.
PCR restriction fragment length polymorphism was used to determine the frequency of IL-10 and TNF-𝛼 genotypes at -1082A and
-308A, respectively. One-hundred and nineteen out of 238 infants had RDS (50%). The age of the mothers and gestational age
ranged 17–45 (mean: 28.6 ± 5.3) years and 24–34 (mean: 34.3 ± 2.38) weeks, respectively. Totally, 23 deaths were recorded in the
RDS group. Incidence of TNF-𝛼-308 A/A and TNF-𝛼-308 G/A was 84% and 16%, respectively. TNF-a-308 G/G was not found in
both groups. Prevalence of IL-10-1082 G/G and IL-10-1082 G/A variants was 65.5% and 34.5%, respectively. IL-10-1082 A/A was not
found in both groups.The incidence of the allele G in the IL-10-1082 polymorphism was lower in RDS group (𝑃 < 0.05). We found
that the risk of RDS was correlated to sex, gestational age, and IL-10-1082.
1. Introduction
Respiratory distress syndrome (RDS) occurs mainly in
preterm infants and its incidence is inversely correlated with
gestational age and birth weight. It is also known as hyaline
membrane disease which is a breathing disorder of mainly
premature babies. In healthy infants, the alveoli—the small,
air-exchanging sacs of the lungs—are coated by surfactant,
which is a soap-like material produced in the lungs as the
fetusmatures in preparation for birth. If premature newborns
have not yet produced enough surfactant, they are unable to
open their lungs fully to breathe which cause RDS [1, 2]. RDS
isamultifactorialdisease[2].The riskofRDSriseswithincreas-
ing prematurity. Babies born before 29 weeks of gestation
have a 60 percent chance of developing RDS [1, 2], but babies
born at full term rarely develop this condition. Maternal
risk factors for preterm birth include previous preterm birth,
periodontal disease, low maternal body mass, poor prenatal
care, poverty, being uninsured, and being a member of a
minority group [1, 2].The risk of RDS increases withmaternal
diabetes, multiple births, cesarean delivery, asphyxia, cold
stress, and maternal history of affected infant [1, 2].
The incidence of RDS in preterm male or white infants
is higher than other groups of patients. RDS affects about 1
percent of newborn infants and is the leading cause of death
in babies who are born prematurely [3, 4]. About 10 percent
of premature babies in the United States develop RDS each
year [3, 4].
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Surfactant deficiency is the primary cause of RDS. Vari-
ation in the genetic profile of RDS can also influence the
incidence of disease in infant populations [5–8].Themost tal-
ented candidates for the surfactant deficiency that have been
identified to date lie in the genes coding for the lung-specific
proteins and surfactant-associated genes and especially those
for SP-A, SP-B, SP-C and SP-D proteins. Indeed, polymor-
phisms in these genes have been associatedwith susceptibility
to RDS [9]. These 4 major proteins play an important role
in the function of surfactant. Documented data revealed that
occurrence of polymorphism in these genes is responsible for
incidence of RDS [10]. Previous evidences showed that respi-
ratory and intestinal inflammations were involved in occur-
rence of RDS [11, 12]. Decisive role of cytokines as important
regulators of surfactant should also be considered [13].
Cytokines may be the regulators of surfactant metabolism in
the preterm infant [10–13], with SP-A, SP-B, SP-C, and SP-D
proteins being involved in the maintenance of an infection-
free and inflammation-free lung [10–13]. Even low levels
of proinflammatory cytokines in the pregnancy period can
reduce the risk of RDS in premature infants [14]. Proin-
flammatory reactions are characterized by production of
cytokines and inflammatory cells that increases permeability
of alveolar capillaries which can be associated with disorder
in lung function [15]. Postnatal activation of circulating
neutrophils and lymphocytes is another indicator of systemic
inflammatory reaction which may contribute to tissue injury
in preterm infants with RDS [16]. Moreover, it has been
shown that, in preterm infants with RDS, the activation of
circulating polymorphonuclear leukocytes has a role in the
pathogenesis of this syndrome [16, 17].
Interleukin- (IL-) 10 is an important immunoregulatory
cytokine which controls inflammatory process by suppress-
ing the expression of proinflammatory cytokines [18]. Docu-
mented data showed that preterm infants with RDS harbored
the higher levels of IL-10 than those without RDS and full-
term newborn [19]. Besides, infants who suffered from RDS
had the higher levels of tumor necrosis factor- (TNF-) 𝛼
than those without RDS [20]. Previous study demonstrated
that the TNF-𝛼 was a potent inhibitor of surfactant protein-
A [21]. In addition, IL-10 is an important anti-inflammatory
cytokine that modulates proinflammatory cytokine such as
TNF-𝛼 [22]. Therefore, anti- and proinflammatory cytokines
are important factors in development of RDS in infants
[23]. Promoter regions of some of the key cytokine genes
contain polymorphisms which can directly influence pro-
duction of cytokines [24]. Therefore, abnormal cytokine
production derived from specific polymorphisms can have
effect on development of RDS. The present study was aimed
at investigating the distribution of IL-10 and TNF-𝛼 gene
polymorphisms and their association with the risk of RDS in
preterm infants.
2. Materials and Methods
2.1. Ethical Issues. The study was approved by the Ethical
Committee of Research of the Hajar Hospital, Iran, and
Shahrekord University of Medical Sciences (ethical code: 90-
10-31) and informed consents were obtained from the families
of the patients. All families gave written informed consents
to participate in the study and answered a questionnaire
about symptoms and history of their diseases. The authors
tried to protect the life, health, dignity, integrity, rights to
self-determination, privacy, and confidentiality of personal
information of studied patients. Information regarding the
demographic data, such as mother age, gestational age, sex,
Apgar score, and the need for mechanical ventilator or
surfactant, was recorded.
2.2. Samples. This cross-sectional, case-control study was
done on Cellular and Molecular Research Center of Shah-
rekord University of Medical Sciences, Shahrekord, Iran.
FromSeptember 2011 toMay 2013, a total of two-hundred and
thirty-eight cord blood samples were collected from preterm
neonates born pediatrics hospitalized in Hajar Hospital, Iran.
Premature infants were classified into two groups: preterm
newborns without RDS (𝑛 = 119) and those with RDS (𝑛 =
119). The gestational age in both groups was less than 37
weeks.
2.3. Inclusion and Exclusion Criteria. The inclusion criteria
for control group were healthy newborn with gestational age
less than 37 weeks.The case group included preterm neonates
with RDS. RDS in pretermnewbornswas diagnosed based on
the clinical criteria including grunting, intercostal retraction,
nasal flaring, cyanosis, and tachypnea and also radiological
findings such as chest radiographs with a diffuse reticulo-
granular pattern and air bronchograms. Preterm newborns
with thoracic and cardiac defects, continuous medication
infusion, and genetic syndromes were excluded from the
study.
2.4. Laboratory Tests. Cord blood samples were collected
in tubes containing EDTA and were stored at −20∘C until
DNA extraction. Genomic DNA was extracted by stan-
dard phenol chloroform method [25]. DNA segments of
TNF-𝛼 and IL-10 genes were amplified using primers IL-
10F CCAGGTAGAGCAACACTCCT/IL-10R CTCTTA-
CCTATCCCTACTTCCGC (156 bp) for IL-10 and TNF-
𝛼 F AATAGGTTTTGAGGGCCATG/TNF-RTCATCTGG-
AGGAAGCGGTAG (234 bp) for TNF-𝛼. The PCR mixture
for IL-10 consisted of 0.2 𝜇M of each primer, 0.2mM dNTPs,
1x PCR buffer, 2mM MgCl2, and 0.2 𝜇L Taq polymerase
(Sinagen, Iran) and for TNF-𝛼, 0.2 𝜇M of each primer,
0.12mM dNTPs, 1x PCR buffer, 2mM MgCl2, and 0.2 𝜇L
Taq polymerase in total volume of 25𝜇L. IL10 was amplified
under a thermal condition consisting of 95∘C for 6min
followed by 37 cycles of 95∘C for 30 s, 55.2∘C for 30 s, and 72∘C
for 40 s and a final extension for 2min at 72∘C. For TNF-𝛼, the
thermal condition consisted of 95∘C for 2min followed by 34
cycles of 95∘C for 30 s, 55∘C for 30 s, and 72∘C for 40 s and the
final extension at 72∘C for 2min.The amplified products were
separated by polyacrylamide gel electrophoresis followed by
silver staining at 45mA for 1.5 hours.
2.5. Genotyping of the Polymorphisms. Genotyping status
of PCR products was determined by restrictive fragmented
length polymorphism (RFLP) assay. PCR products of IL-10
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Table 1: Some characters of infants in the study groups.
Variable Control RDS
∗
𝑃 value
(Mean ± SD∗∗) (Mean ± SD)
Mother age 29.2 ± 5.8 28.1 ± 4.7 0.109
Gestational age 35.6 ± 0.71 33 ± 2.7 <0.001
Sex (Boy) 45 (37.8) 66 (55.5) 0.006
Normal vaginal delivery 28 (23.5) 19 (16) 0.143
Gravid 2.27 ± 1.36 2 ± 1.15 0.139
Apgar score 8.8 ± 0.5 7.5 ± 1.6 <0.001
Duration (day) 8.3 ± 1.9 11.5 ± 7.7 0.312
Surfactant 0 28 (23.5) <0.001
Ventilator 0 33 (27.7) <0.001
Death 0 23 (19.3) <0.001
∗Respiratory distress syndrome, ∗∗standard deviation.
and TNF-𝛼 were subjected to digestion with EarI and NcoI
restriction enzymes (Fermentase, Germany), respectively. All
tests were done according to the manufacturer’s instruction.
The products of digestion were analyzed on 8% polyacry-
lamide gel. EarI restriction enzyme cleaved the variant of
IL-10-1082 G into two distinct fragments of 126 and 30 bp,
while the wild type allele (156 bp) remained intact. The PCR
product of TNF-𝛼G-308 A variant was also digested by NcoI
restriction enzyme and showed two distinct bands of 218 bp
and 16 bp and wild type allele remained uncleaved (234 bp).
2.6. Statistical Analysis. Continuous variables are presented
as mean ± SD and categorical ones as frequency. Com-
parisons between the two groups were made using the
Chi-square and Fisher’s exact tests for categorical variables
and independent 𝑡-test for continuous variables. Logistic
regression was performed to modify the association of IL-
10-1082 genotype and sex and gestational age of pediatrics.
Statistical analysis was done by SPSS version 18 software and
𝑃 value of 0.05 was considered as statistically significant.
3. Results
3.1. Study Population and Prevalence of RDS. Two-hundred
thirty-eight infants participated in this study, of whom 119
had RDS (50%), 119 were controls, and 111 (46.6%) were male.
The age of the mothers ranged 17–45 (mean: 28.6±5.3) years.
The gestational age ranged 24–34 (mean: 34.3 ± 2.38) weeks.
The characters of the participants are shown in Table 1. We
found that the mean distribution of the age of the mothers,
gestational age, and frequency of boy patient in control and
RDS groups were 29.2 ± 5.8 and 28.1 ± 4.7 years, 35.6 ±
0.71 and 33 ± 2.7 weeks, and 37.8% and 55.5%, respectively.
Prevalence of normal vaginal delivery in control and RDS
groups was 23.5% and 16%, respectively (𝑃 = 0.143). We also
found that the mean gestational age was significantly lower
in RDS patients than control group (𝑃 < 0.05). Infants with
RDS had significantly lower Apgar score (𝑃 < 0.05). Need for
mechanical ventilator and surfactantwas not applicable to the
control group.There were 23 deaths in the RDS group but no
death was reported in the control group (𝑃 < 0.05).
Table 2: Distribution of TNF-𝛼-308 polymorphism, need for
mechanical ventilator and surfactant and death in various cate-
gories.
Variable Category A/A G/A Total 𝑃 value
Surfactant Yes 26 (92.9%) 2 (7.1%) 28 (100%) 0.271
No 174 (82.9%) 36 (17.1%) 210 (100%)
Ventilator Yes 31 (93.9%) 2 (6.1%) 33 (100%) 0.094
No 169 (82.4%) 36 (17.6%) 205 (100%)
Death Yes 22 (95.7%) 1 (4.3%) 23 (100%) 0.139
No 178 (82.8%) 37 (17.2%) 215 (100%)
Table 3: Distribution of IL-10-1082 polymorphism, need for
mechanical ventilator and surfactant and death in various cate-
gories.
Variable Category G/G G/A Total 𝑃
Surfactant Yes 16 (57.1%) 12 (42.9%) 28 (100%) 0.319
No 140 (66.7%) 70 (33.3%) 210 (10%)
Ventilator Yes 19 (57.6%) 14 (42.4%) 33 (100%) 0.299
No 137 (66.8%) 68 (33.2%) 205 (100%)
Death Yes 13 (56.5%) 10 (43.5%) 23 (100%) 0.338
No 143 (66.5%) 72 (33.5%) 215 (100%)
3.2. Distribution of TNF-𝛼-308 Polymorphism. Figure 1 rep-
resents the PCR product of IL gene and also genotyping of
IL polymorphism by PCR-RFLP. Figure 2 represents the PCR
product of TNF gene and also digestion of PCR product
by NcoI. The distribution of TNF-𝛼-308 polymorphism in
various groups of study is shown in Table 2. Total incidence
of TNF-𝛼-308 A/A and TNF-𝛼-308 G/A was 84% and 16%,
respectively. TNF-a-308 A/A and TNF-a-308 G/A prevalence
were evaluated according to need of surfactant (92.9% and
7.1%), need of mechanical ventilation (93.9% and 6.1%),
and death (95.7% and 4.3%). These three groups showed
higher prevalence of TNF-a-308 A/A (𝑃 < 0.05) and lower
prevalence of TNF-a-308 G/A (𝑃 < 0.05). TNF-𝛼-308 G/G
was not found in both groups.
3.3. Distribution of Interleukins Polymorphism. Distribution
of IL-10-1082 polymorphisms in various studied groups is
shown in Table 3. IL-10-1082 G/G and G/A prevalence
were evaluated according to need of surfactant (57.1% and
42.9%), need of mechanical ventilation (57.6% and 42.4%),
and death (56.5% and 43.5%). These three groups showed
higher prevalence of IL-10-1082 G/A (𝑃 < 0.05) and lower
prevalence of IL-10-1082 G/G (𝑃 < 0.05). Total prevalence of
IL-10-1082 G/G and IL-10-1082 G/A variants was 65.5% and
34.5%, respectively. IL-10-1082 A/A was not found in both
groups. IL-10-1082 G/A had a significantly higher incidence
in the pediatric patients of RDS group (𝑃 < 0.05), while IL-
10-1082 G/G had a significantly lower incidence in this group
(𝑃 < 0.05).
3.4. Allele’s Absolute Frequencies of TNF-𝛼-308 and IL-10-1082
Polymorphisms. The allele’s absolute frequencies of TNF-𝛼-
308 and IL-10-1082 polymorphisms in various studied groups
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Figure 1: (a) PCR product of IL gene corresponding to a 156 bp band; M: 100 bp DNA ladder, lane 3: negative control, lanes 1, 2, 4, and 5:
samples. (b) Genotyping of IL polymorphism by PCR-RFLP, M: 100 bp DNA ladder; subjects 1, 2, 3, 6, and 8: homozygotes for the G allele;
subjects 4, 5, 7, and 9: heterozygotes for the A/G allele.
200 bp
300 bp
M123456
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Figure 2: (a) PCR product of TNF gene corresponding to a 234 bp band; M: 100 bp DNA ladder, lane 1: negative control, lanes 2, 3, 4, 5, and 6:
samples. (b) Digestion of of PCR product by NcoI, M: 100 bp DNA ladder; lane 1: homozygote for the G allele; lanes 4, 7, and 9: heterozygotes
for the A/G allele; lanes 2, 3, 5, 6, and 8: homozygotes for the A allele.
are shown in Table 4.We found that the incidence of the allele
G in the IL-10-1082 polymorphism was significantly lower in
RDS group (𝑃 < 0.05). On the other hand, pediatric patients
of the RDS group had the higher prevalence of TNF-𝛼-308
A/A (𝑃 = 0.479) and IL-10-1082 G/A (𝑃 = 0.014).
3.5. Results Obtained from Logistic Regression. The result of
logistic regression is shown in Table 5. We found that the risk
of RDS was significantly related to the three variables of sex,
gestational age, and IL-10-1082.
4. Discussion
The present investigation was done in order to determine
of the association of IL-10-1082 G/A and TNF-𝛼-308 A pro-
moter polymorphisms and incidence of RDS in a population
of preterm infants in Iran. Our findings showed that the risk
of RDS was significantly lower in preterm infants with the
IL-10-1082 G/G genotype, suggesting a protective role of this
variant in occurrence of RDS. We also found no significant
association between TNF-𝛼G-308A polymorphism and inci-
dence of RDS in preterm newborns.
IL-10 is a significant immunoregulatory cytokine that is
mostly produced by monocytes, macrophages, B cells, and T
cells. It controls the inflammatory procedures by suppressing
the expression of proinflammatory cytokines, chemokines,
adhesion molecules, and antigen-presenting and costimula-
tory molecules in monocytes/macrophages, neutrophils, and
T cells [18, 26–28]. Several investigations of complex diseases
have indicated a main role for IL-10 in chronic inflamma-
tory disorders that are considered by the predominance of
cytokines such as IL-1, IL-6, IL-8, IL-10, IL-12, and TNF.
These included Crohn’s disease, psoriasis, multiple sclerosis,
and rheumatoid arthritis [18, 26–28]. The exact mechanisms
involved in the regulation of IL-10 production endure to
be determined, although inherited factors seem to have
imperative roles. A difference in IL-10 secretion in association
with a Single Nucleotide Polymorphism (SNP) in the -
1082 position of the gene promoter has been established. In
particular, an association of the -1082 G allele with a high IL-
10 producing ability has been shown, through assessments of
bothmRNAandprotein [18, 26–28].The IL-10-1082G/ASNP
is locatedwithin an Ets binding site.The -1082A allele confers
a higher binding empathy to the transcription factor PU.1,
which inhibits gene expression and leads to decreased IL-10
expression in individuals carrying this allele [18, 26–28]; thus,
it is reasonable that the IL-10-1082GG andGA genotypes also
have high expression rates in the premature lung.
G/G polymorphism of the IL-10-1082 has been reported
to be a protecting factor against pulmonary diseases and
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Table 4: Frequency of genotype or allele of TNF-𝛼-308 and IL-10-1082 polymorphism in different groups of pediatrics.
Polymorphism Genotype/allele Control (𝑁 (%)) RDS∗ (𝑁 (%)) 𝑃 OR (95% CI)
TNF-alpha-308
AA 98 (82.4) 102 (87.7) 0.479 0.778 (0.387–1.561)
GA 21 (17.6) 17 (14.3)
A allele 217 (91.2) 221 (92.9) 0.499 0.795 (0.408–1.548)
G allele 21 (8.8) 17 (7.1)
IL-10-1082
GG 87 (73.1) 69 (58) 0.014 1.97 (1.143–3.397)
GA 32 (26.9) 50 (42)
G allele 206 (86.6) 188 (79) 0.029 1.712 (1.053–2.783)
A allele 32 (13.4) 50 (21)
∗Respiratory distress syndrome.
Table 5: Result of logistic regression for dependent variable of groups.
Variable Coefficient SE∗ of coefficient Sig. OR 95% CI for OR
Lower Upper
IL-10-1082 0.513 0.186 0.006 1.671 1.16 2.408
Gestational age −1.303 0.189 <0.001 0.272 0.187 0.394
Sex −0.699 0.352 0.047 0.497 0.25 0.991
Constant 45.663 6.679 <0.001 — — —
∗Standard error.
especially acute RDS and active tuberculosis [29, 30]. Results
of the previous investigations showed that IL-10-1082 G/G
genotype had the lower incidence among critically ill patients
with organ failure compared with healthy one [29, 30].
Significant associations between the presence of IL-10-1082
G/G polymorphism and lower incidence and mortality rate
of diseases were found in patients who suffered from acute
respiratory distress syndrome (ARDS) [29] whichwas similar
to our findings.
G to A SNP at a position of 1082 are important for reg-
ulation of IL-10 transcription. Individuals with GG genotype
have higher levels of IL-10 transcription. Besides, those with
higher levels of GG genotype have also higher concentrations
of circulating IL-10 in both in vivo and in vitro conditions
[31, 32]. Lower levels of IL-10 were found in patients with
acute RDS compared with those without ARDS [33] which
was similar to our findings. Yanamandra et al. (2005) [34]
reported that the IL-10-1082 A allele (for lower IL-10 produc-
tion) had a minor effect on the combined outcome of death
or bronchopulmonary dysplasia.
Our finding is similar to the result of Capasso et al.
(2007) [23] whichwas conducted on Italian pretermnewborn
population. They showed that the risk of RDS was signifi-
cantly lower in IL-10-1082 GG/GA positive preterm newborn
pediatrics than those which were positive for A/A genotype.
Results of the previous research reported the substantial anti-
inflammatory effects of recombinant IL-10 in the cases of
RDS [35] which was similar with our results. The balance
between anti- and proinflammatory cytokines is important
in response to injuries and acute RDS [36]. Imbalance
between anti- and proinflammatory cytokines is responsible
for increase in cytokine response and organ sequelae during
neonatal infection in preterm infant [37].
Our results represented that infant patients of the RDS
group had a significantly higher prevalence of TNF-𝛼-308
A/A and IL-10-1082G/A. Release of IL-10 (anti-inflammatory
cytokines) has been shown to be upregulated by circulating
TNF-𝛼 (proinflammatory cytokine) [37, 38]. IL-10 has also
the ability to suppress the synthesis of proinflammatory
cytokines and of effectively downregulating proinflammatory
response [39]. IL-10 attenuates the proinflammatory response
in sepsis and decreases mortality in some animal model [40].
Massive proinflammatory reaction with severe organ dys-
function will occur in the cases of anti- and proinflammatory
cytokines imbalance [41].
Concentration of IL-10 in the bronchoalveolar lavage
fluid of preterm infant ventilated due to RDS has been signifi-
cantly raised over the first five postnatal days [42]. Exogenous
administration of IL-10 will protect against excessive proin-
flammatory cytokine production andmortality [43]. Neutral-
ization of endogenous IL-10 with monoclonal antibodies will
increase the levels of proinflammatory cytokine and fatality
rate [44].
We found that presence of IL-10-1082 G/A increased the
susceptibility to RDS. IL-10-1082 G/A genotype is associated
with lower production of IL-10 and also consequent increase
in the proinflammatory cytokine is associated with occur-
rence of RDS. We also found that the incidence of IL-10-1082
G allele in RDs group was significantly lower than control. G
allele has been associated with increase in IL-10 production
and decrease in proinflammatory cytokine production which
can reduce the risk of RDS [31].
This study also examined the effect of the TNF-𝛼-308 A
polymorphism on the risk of RDS. We found no significant
difference in the incidence of genotype or allele between the
control and RDS groups of preterm infants. However, the
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dramatic inhibitory effect of TNF-𝛼 on surfactant protein
expression was also reported previously [21]; we found no
significant association between the presence of TNF-𝛼-308
A, IL-10-1082 G polymorphisms with wild type allele with
need for mechanical ventilator and surfactant and mortality
rate in preterm infants who suffered from RDS. Andalas et al.
(2016) [45] reported that the concentration of TNF-𝛼between
preterm and control groups was not statistically different, 5.5
± 2.9mg/dL versus 10.1 ± 17.9mg/dL, 𝑃 = 0.112. They also
showed that the level of TNF-𝛼 had no strong association
with either genotype distribution or allele frequency of SNP
-308 G/A TNF-𝛼 which was similar to our findings. Gong et
al. (2005) [46] represented that the TNF-𝛼-308A and TNFB1
alleles were in linkage disequilibrium in the cases of acute
RDS. They showed that these polymorphisms were not asso-
ciated with acute RDS susceptibility which was similar to our
results.The TNF-𝛼-308A allele was associated with increased
60-daymortality in acute RDS, with the strongest association
found among younger patients. They also reported that there
was no association between the TNFB polymorphism and
ARDS mortality. Li et al. (2013) [47] in their meta-analysis
study reported that throughout twelve case-control studies
and one cohort study analyzed, no association between TNF-
𝛼-308A/G polymorphism and pneumonia risk was observed
for AA + AG genotypes. They also indicated that TNF-𝛼-
308A/G polymorphism was not associated with pneumonia
mortality (𝑃 = 0.07). Furthermore, there was no association
of TNF-𝛼-238A/Gpolymorphismwith the risk of pneumonia
(𝑃 = 0.20). Similar results were reported by Kazzi et al.
(2004) [48]. They showed that the genotypic distributions of
lymphotoxin-𝛼250 and TNF-𝛼308 were comparable among
the groups of infants. However, the AA and GA TNF-𝛼238
genotypes were much less likely to occur among infants with
bronchopulmonary dysplasia than among healthy infants.
The adenine allele of TNF-𝛼238 was absent among infants
with severe bronchopulmonary dysplasia and occurred sig-
nificantly less often among infants with moderate or severe
bronchopulmonary dysplasia, compared with infants with
mild bronchopulmonary dysplasia. They finally concluded
that the adenine allele of TNF-𝛼238 may reduce the risk and
severity of bronchopulmonary dysplasia.
5. Conclusion
In conclusion, we found that some genotypes are associated
with the risk of RDS. The IL-10-1082 G/G genotype signif-
icantly reduced the possibility of RDS and IL-10-1082 G/A
genotype increased susceptibility to RDS, while no associa-
tion was found between TNF-𝛼-308 A polymorphism and
RDS in preterm newborns. Our investigation also showed
no association between the presence of TNF-𝛼-308 A, IL-
10-1082 G polymorphisms and wild type allele with need for
mechanical ventilator and surfactant and mortality rate in
preterm infants who suffered from RDS.
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